Wave Life Sciences Ltd. — Director's Dealing 2023

Feb 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2023-02-16

Reporting Person: Moran Kyle (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-16	Ordinary Shares	S	9729	$4.04	Disposed	79751	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-17	Share Option (right to buy)	$4.75	A	272700	Acquired	2033-02-17	Ordinary Shares (272700)	Direct

Footnotes

F1: On February 16, 2023, the reporting person sold 9,729 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

F2: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3: Includes 1,500 ordinary shares acquired on July 14, 2022, and 3,413 ordinary shares acquired on January 14, 2023, under the issuer's 2019 Employee Share Purchase Plan.

F4: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.